1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 14, 10/Apr/2025
  4. Article
Surveillance Open Access
Like 0
Download

SDG 3: Antimicrobial resistance

Abstract

Background

Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens. It was selected for the government’s subscription model pilot, for incentivising new antibiotic development, which began in December 2020.

Aim

Ahead of the pilot, we assessed ceftazidime/avibactam testing, resistance (2016−2020) and usage (2017−2020) levels in England, as baselines for future surveillance.

Methods

From routine surveillance samples, we retrieved reported ceftazidime/avibactam resistance categorisation. From reference laboratory samples, we reviewed minimum inhibitory concentration (MICs) and molecular data. Among surveillance samples, per cent resistance was estimated. Referred samples’ MICs, by carbapenemase gene presence, were investigated. Ceftazidime/avibactam hospital use was measured in defined daily doses (DDDs).

Results

Overall, 6.3% (4,200/66,914; 95% confidence interval (95%CI): 6.1–6.4%) of surveillance-reported ceftazidime/avibactam-tested Gram-negative bacteria were resistant. Percentage resistance per bacterial species varied over time, somewhat stabilising as testing was established, with between April 2019 and March 2020, 1.3% (288/22,736; 95%CI: 1.1−1.4%), 12.6% (690/5,495; 95%CI: 11.7−13.5%) and 6.1% of (314/5,179; 95%CI: 5.4−6.7%) being resistant. For 8,437 referred Enterobacterales, MIC determination found 11.5% (968/8,437; 95%CI: 10.8–12.2%) resistant. Among resistant isolates, 89.3% (864/968; 95%CI: 87.1–91.1%) had metallo-β-lactamase (MBL) genes. Of 908 MBL-negative isolates, producing ≥ 1 non-metallo-carbapenemase(s), 2.1% (19/908; 95%CI: 1.3–3.2%) were resistant. Since March 2017, 69.5% (105/151) of English National Health Service Trusts used ceftazidime/avibactam. Monthly usage progressed from 21 to 744 DDDs in March 2020.

Conclusion

For appropriate treatment, carbapenemase gene detection and variant identification in ceftazidime/avibactam surveillance matters. Detecting emerging resistant pathogens and preventing spread within healthcare settings requires vigilance.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.14.2400399
2025-04-10
2025-04-14
/content/10.2807/1560-7917.ES.2025.30.14.2400399
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/14/eurosurv-30-14-4.html?itemId=/content/10.2807/1560-7917.ES.2025.30.14.2400399&mimeType=html&fmt=ahah

References

  1. Suda KJ, Traversa A, Patel U, Poggensee L, Fitzpatrick MA, Wilson GM, et al. Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE). Infect Control Hosp Epidemiol. 2023;44(4):674-7.  https://doi.org/10.1017/ice.2021.452  PMID: 34814961 
  2. Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675-92.  https://doi.org/10.1007/s40265-018-0902-x  PMID: 29671219 
  3. European Centre for Disease prevention and Control (ECDC). Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae. ECDC Rapid Risk Assessment. Stockholm: ECDC; 2018. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA - Emergence of resistance to CAZ-AVI in CRE Enterobacteriaceae - final.pdf
  4. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18-27.  https://doi.org/10.1016/j.jgar.2019.12.009  PMID: 31863899 
  5. Coppi M, Di Pilato V, Monaco F, Giani T, Conaldi PG, Rossolini GM. Ceftazidime-Avibactam Resistance Associated with Increased blaKPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(4):e01816-19.  https://doi.org/10.1128/AAC.01816-19  PMID: 31964792 
  6. Spiliopoulou I, Kazmierczak K, Stone GG. In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17). J Antimicrob Chemother. 2020;75(2):384-91.  https://doi.org/10.1093/jac/dkz456  PMID: 31742604 
  7. Livermore DM, Meunier D, Hopkins KL, Doumith M, Hill R, Pike R, et al. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. J Antimicrob Chemother. 2018;73(3):648-57.  https://doi.org/10.1093/jac/dkx438  PMID: 29228202 
  8. Bianco G, Boattini M, Bondi A, Comini S, Zaccaria T, Cavallo R, et al. Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures. J Hosp Infect. 2022;122:217-9.  https://doi.org/10.1016/j.jhin.2022.02.001  PMID: 35139426 
  9. Di Bella S, Giacobbe DR, Maraolo AE, Viaggi V, Luzzati R, Bassetti M, et al. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. J Glob Antimicrob Resist. 2021;25:268-81.  https://doi.org/10.1016/j.jgar.2021.04.001  PMID: 33895414 
  10. Räisänen K, Koivula I, Ilmavirta H, Puranen S, Kallonen T, Lyytikäinen O, et al. Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018. Euro Surveill. 2019;24(19):2-4.  https://doi.org/10.2807/1560-7917.ES.2019.24.19.1900256  PMID: 31088601 
  11. National Institute for Health and Care Excellence (NICE). Models for the evaluation and purchase of antimicrobials. 2022. Available from: https://www.nice.org.uk/about/what-we-do/life-sciences/nice-advice-service/models-for-the-evaluation-and-purchase-of-antimicrobials
  12. Robinson J. First antimicrobial drugs purchased via new ‘subscription’ payment model. Pharm J. 2020.  https://doi.org/10.1211/PJ.2020.20208686 
  13. UK Health Security Agency. Laboratory reporting to UKHSA: a guide for diagnostic laboratories. London: UKHSA; 2023. Available from: https://assets.publishing.service.gov.uk/media/647749ce5f7bb700127fa25a/UKHSA_Laboratory_reporting_guidelines_May_2023.pdf
  14. UK Health Security Agency. Bacteriology Reference Department User Manual. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/bacteriology-reference-department-brd-user-manual
  15. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. 2020. Available from: http://www.eucast.org.
  16. Turton JF, Perry C, Elgohari S, Hampton CV. PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. J Med Microbiol. 2010;59(Pt 5):541-7.  https://doi.org/10.1099/jmm.0.015198-0  PMID: 20110386 
  17. National Health Service England (NHS England). Hospital Episode Statistics. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics; 2021.
  18. Norwegian Institute of Public Health WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical/Daily Defined Dose (ATC/DDD) index 2019. ATC/DDD Index. 2020. Available from: https://atcddd.fhi.no/atc_ddd_index/
  19. Surabhi Taori AF. Kirstin Khonyongwa, Nergish Desai, editor. Emergence of new high-level aminoglycoside-resistant dual carbapenemase KPC/OXA-48-producing Klebsiella pneumoniae. ECCMID; 2018; Madrid, Spain.
  20. National Institute for Health and Care Excellence (NICE). Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections. Health Technology Evaluation. 2022. [Accessed 4 Jan 2024]. Available from: https://www.nice.org.uk/about/what-we-do/life-sciences/scientific-advice/models-for-the-evaluation-and-purchase-of-antimicrobials/ceftazidime-with-avibactam
  21. UK Health Security Agency. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report 2020-21. London: UKHSA; 2021. Available from: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
  22. Glover RE, Singer AC, Roberts AP, Kirchhelle C. The antibiotic subscription model: fostering innovation or repackaging old drugs? Lancet Microbe. 2023;4(1):e2-3.  https://doi.org/10.1016/S2666-5247(22)00235-X  PMID: 36154717 
  23. Public Health England. New statutory duty on reporting results of antimicrobials susceptibility testing. Heal Prot Rep. 23/12/2020. 2020;14(17). Available from: https://www.gov.uk/government/publications/health-protection-report-volume-14-2020/hpr-volume-14-issue-17-29-september-and-5-october#new-statutory-duty-on-reporting-results-of-antimicrobial-susceptibility-testing
  24. Bennet KF, Guy RL, Gerver SM, Hopkins KL, Puleston R, Brown CS, et al. Determining the impact of professional body recommendations on the screening of acquired carbapenemase-producing Enterobacterales in England. Infect Prev Pract. 2023;5(2):100281.  https://doi.org/10.1016/j.infpip.2023.100281  PMID: 37151818 
  25. Guy R, Higgins H, Rudman J, Fountain H, Bennet KF, Hopkins KL, et al. Antimicrobial Resistance in England 2017 to 2021 (ESPAUR Report 2021-22). Med. Sci. Forum 2022, 15(1):3;
  26. Compain F, Arthur M. Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase. Antimicrob Agents Chemother. 2017;61(7):e00451-17.  https://doi.org/10.1128/AAC.00451-17  PMID: 28461318 
  27. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018;73(6):1525-9.  https://doi.org/10.1093/jac/dky082  PMID: 29566151 
  28. Bianco G, Boattini M, Iannaccone M, Cavallo R, Costa C. Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay. J Antimicrob Chemother. 2020;75(10):3075-6.  https://doi.org/10.1093/jac/dkaa283  PMID: 32676660 
  29. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother. 2015;59(9):5324-30.  https://doi.org/10.1128/AAC.00678-15  PMID: 26100712 
  30. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017;61(3):e02097-16.  https://doi.org/10.1128/AAC.02097-16  PMID: 28031201 
  31. Gordon J, Gheorghe M, Goldenberg S, Miller R, Dennis J, Al-Taie A. Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom. PharmacoEconomics. 2023;41(12):1657-73.  https://doi.org/10.1007/s40273-023-01310-6  PMID: 37587392 
  32. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. , Antibacterial Resistance Leadership Group. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163-71.  https://doi.org/10.1093/cid/cix783  PMID: 29020404 
  33. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumonie Bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883-17.  https://doi.org/10.1128/AAC.00883-17  PMID: 28559250 
  34. Wilson GM, Fitzpatrick M, Walding K, Gonzalez B, Schweizer ML, Suda KJ, et al. Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis. 2021;8(2):ofaa651.  https://doi.org/10.1093/ofid/ofaa651  PMID: 33598503 
  35. Satlin MJ, Chen L, Gomez-Simmonds A, Marino J, Weston G, Bhowmick T, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Clin Infect Dis. 2022;75(12):2066-75.  https://doi.org/10.1093/cid/ciac354  PMID: 35522019 
  36. Hu Q, Chen J, Sun S, Deng S. Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review. Infect Drug Resist. 2022;15:6907-26.  https://doi.org/10.2147/IDR.S390635  PMID: 36465807 
  37. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521-47.  https://doi.org/10.1016/j.cmi.2021.11.025  PMID: 34923128 
  38. Hsu W, Chuang MH, Tsai WW, Lai CC, Lai HY, Tang HJ. Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis. Infection. 2024;52(5):2029-42.  https://doi.org/10.1007/s15010-024-02277-y  PMID: 38739208 
  39. UK Health Security Agency (UKHSA). English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) Report 2022 to 2023. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
  40. Public Health England (PHE). English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report 2019-20. London: PHE; 2020. Available from: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Rebecca+L+Guy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guy Rebecca L</a>, <a href="/search?value1=Katie+L+Hopkins&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hopkins Katie L</a>, <a href="/search?value1=Emma+L+Budd&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Budd Emma L</a>, <a href="/search?value1=Kate+Wilson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wilson Kate</a>, <a href="/search?value1=Holly+Fountain&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fountain Holly</a>, <a href="/search?value1=Dani%C3%A8le+Meunier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meunier Danièle</a>, <a href="/search?value1=Rachel+Pike&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pike Rachel</a>, <a href="/search?value1=Sarah+M+Gerver&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gerver Sarah M</a>, <a href="/search?value1=Roshina+Gnanadurai&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gnanadurai Roshina</a>, <a href="/search?value1=Colin+S+Brown&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brown Colin S</a>, <a href="/search?value1=Susan+Hopkins&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hopkins Susan</a>, <a href="/search?value1=Berit+Muller-Pebody&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Muller-Pebody Berit</a></span>. The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(14):pii=2400399. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.14.2400399" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.14.2400399</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 Jun 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 09 Dec 2024 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.14.2400399
/content/10.2807/1560-7917.ES.2025.30.14.2400399
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error